newsfilter
← Latest News
GlobeNewswire·

Icosavax Reports First Quarter 2022 Financial Results and Provides Corporate Update

- Enrollment completed in older adults portion of Phase 1/1b trial of IVX-121, a virus like particle (VLP) vaccine candidate displaying the prefusion stabilized Respiratory Syncytial Virus (RSV) F antigen - - Topline, interim Phase 1/1b data for IVX-1